MRC1 and colorectal cancer: The anti-cancer activity of cannabinoids CBD and 4’-F-CBD was assessed against a vector control GBM cell line (U373-V) and two cell lines representing common resistance mechanisms to treatment with TMZ (U373-M, MGMT-transfected U373-V isogenic partner, and MMR-deficient HCT116 colorectal cancer).